TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform
Special Notice from Department of Energy.
Data as of Oct 24, 2026. Sources: SAM.gov and Grants.gov. Snapshot govcon-directory-20261024T104923Z-2151694.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services. Counts and totals are computed by DSE from public SAM.gov and Grants.gov notices. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Closing in 41 days
Notice details
- Agency
- Department of Energy
- Sub-tier agency
- ENERGY, DEPARTMENT OF
- Notice type
- Special Notice
- Solicitation number
- S-195396
- Product/service code
- 6505
- Place of performance
- Los Alamos, New Mexico
- Posted
- Jun 5, 2026
- Response deadline
- Dec 4, 2026
- Source
- SAM.gov
Description
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations. The Opportunity: Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable
Summarized from the official notice. The description is shortened; read the full text on the official notice.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →Frequently asked questions
When is the response deadline?
The published deadline is Dec 4, 2026. That is 41 days after the data date.
What NAICS code applies?
NAICS 325412, Pharmaceutical Preparation Manufacturing.
Which agency issued this notice?
Department of Energy.
Where is the official notice?
The link under Official notice opens the source listing.